OTCPicks.com Stocks to Watch for Wednesday, September 19th

OTCPicks Publisher Newsletter

OTCPicks.com Stocks to Watch for Wednesday, September 19th UTRM, WAXS, DITC, OXGN, BPAX, DARA Our Stocks to Watch today include United Treatment Centers Inc. (OTC:

UTRM), World Access Inc. (OTC: WAXS), Ditech Networks Inc. (Nasdaq: DITC), OXiGENE Inc. (Nasdaq: OXGN), Biosante Pharmaceuticals Inc. (Nasdaq: BPAX) and DARA BioSciences Inc. (Nasdaq: DARA).

Visit http://otcpicknews.com/emailmarketer/link.phpM940&N46&L1&F=T to register for our Stocks to Watch Newsletter and Email Stock Watch Alerts.

UNITED TREATMENT CENTERS INCORPORATED (OTC: UTRM) “Up 566.67% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N46&L94&F=T Element Trading Technologies foresees the global growth in individuals seeking to trade for themselves and believes it can position itself to become a leader the in the active trader business. With the advancements in digital communication throughout the world the company`s market is unrestricted. China, India, and Russia are among the fastest growing markets for individuals seeking to become active day traders.

UTRM News:

September 18 – Element Trading Technologies, Inc. Announces Reverse Merger Into United Treatment Centers, Inc.

Experienced Management and New Business Plan Focused on Income Growth Through Recurring Revenues Element Trading Technologies Inc., a company which trains market traders to successfully trade stocks with the company`s proprietary trading account, has completed a reverse merger into United Treatment Centers Inc. (OTC:

UTRM). Element Trading Technologies will be filing with FINRA for a company name change and new trading symbol.

Element Trading Technologies recruits and trains stock traders to day trade the company`s proprietary trading account under a tightly-controlled risk-managed basis. Providing a win-win opportunity to build income, Element Trading shares in the trading profits of its traders. Traders pay monthly software and a proprietary program membership fee and are allocated day trading buying power based on their daily equity balance. Traders are paid a percentage of their net profits on a monthly basis as they develop their trading expertise.

Element Trading Technologies will be marketing its services through a number of channels. The digital ad campaign will have the company prominently displayed on prominent financial web sites. The cable television ad campaign is planned for select markets throughout the United States on CNBC, Fox Business News, and Bloomberg News. The ad campaign will drive traffic to Element Trading`s free “Analyst Room” where the company will promote on line webinars that will educate the audience to the company`s services and advantages.

Charles Vaccaro, CEO of Element Trading Technologies, said, “We are very excited to have effected this transaction that offers long time UTRM shareholders the opportunity to be a part of a company with an active business while new investors can participate in a new public investment in a niche growth sector. The scalability of investment online continuing education is what makes our business plan attractive a business plan we have experience with.” Mr. Vaccaro continued, “We have a great deal of experience in building a company training stock traders on how to trade profitably and building an income stream for themselves and their families. The business is out there and our marketing plan is already in place.” Dan Noor, Chief Operating Officer, said, “We welcome all UTRM shareholders to our vision of rapidly building a recurring revenue base as we train our customers to build their own business by trading large cap stocks with stringent risk management. We look forward to updating our shareholders as we build the critical mass for profitability and the momentum for income growth.” WORLD ACCESS INCORPORATED (OTC: WAXS) “Up 375.00% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N46&L49&F=T World Access, Inc. provides wholesale international long distance services and designs a variety of wireline and wireless telecommunications solutions for service providers. The Company`s network solutions include intelligent multi- plexers, digital microwave radio systems, digital switches, billing and network telemanagement systems, cellular base stations, and engineering services.

WAXS News:

No recent news for World Access Inc. (OTC: WAXS).

DITECH NETWORKS INCORPORATED (NASDAQ: DITC) “Up 74.53% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N46&L48&F=T Ditech Networks provides advanced voice processing solutions that enable carriers, enterprises, and consumers to benefit from the power and simplicity of human speech. Ditech Networks is headquartered in San Jose, California.

DITC News:

September 18 – Nuance to Acquire Ditech Networks Ditech Networks Enhances Nuance Voice to Text Business with Technology, Customers and Expertise, and Advances Voicemail to Text Platform Innovation Nuance Communications, Inc. (Nasdaq: NUAN) announced it has signed an agreement to acquire Ditech Networks, Inc. (Nasdaq: DITC). Ditech Networks voice technologies, including the companys Voice Quality Assurance (VQA) technology and PhoneTag voicemail-to-text services, will further enhance Nuances portfolio of mobile and enterprise voice offerings.

As voice is increasingly integrated with a broad array of products and services, people expect seamless interactions that simply work anytime and anywhere. Ditech Networks portfolio of voice technologies will help Nuance continue its pace-setting innovations for carriers, consumers and enterprises across an array of products and services. In particular, Ditech Networks PhoneTag service will enhance Nuances Dragon Voice to Text Services business by adding important customers and complementary technologies, and further advance innovation supporting Nuances highly secure, on-premise voice to text platform.

The worlds most innovative carriers and unified communications providers work with Nuance to take advantage of the revolution in voice recognition, and nowhere is this more evident than in our voicemail to text and call completion businesses, where billions of calls are converted into easily read text and email messages a powerful solution for todays messaging-centric world, said John Pollard, Vice President and General Manager, Voice to Text Services, Nuance Mobile. Acquiring Ditech Networks voice technologies will help Nuance continue to drive these next-generation services.

Nuance has agreed to acquire Ditech Networks for $1.45 per share in cash, representing a total enterprise value of approximately $22.5 million, net of Ditech Networks cash as of the signing date. The transaction has been unanimously approved by the Boards of Directors of each company. The transaction is expected to close late in 2012, subject to Ditech Networks stockholder approval and other closing conditions.

Ditech Networks voice technologies combined with Nuances voice and language understanding portfolio is an exciting proposition for our combined customer and partner base, while providing a unique opportunity to extend the value and benefits of our technologies into new markets, said Ken Naumann, CEO, Ditech Networks.

ABOUT NUANCE COMMUNICATIONS, INC.

Nuance is a leading provider of voice and language solutions for businesses and consumers around the world. Its technologies, applications and services make the user experience more compelling by transforming the way people interact with information and how they create, share and use documents.

Every day, millions of users and thousands of businesses experience Nuances proven applications and professional services.

OXIGENE INCORPORATED (NASDAQ: OXGN) “Up 30.24% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N46&L36&F=T OXiGENE, Inc. develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company`s product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, platinum resistant ovarian cancer, and head-and-neck cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, an ortho-quinone prodrug, which is in Phase I clinical trial for solid tumors.

The company was founded in 1988 and is headquartered in Waltham, Massachusetts.

OXGN News:

September 17 – OXiGENE to Present at BIO CEO & Investor Conference OXiGENE Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT in Anaplastic Thyroid Cancer OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it has come to agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for its Phase 3 clinical trial (FACT 2) of ZYBRESTAT for the treatment of anaplastic thyroid cancer (ATC). The FACT 2 study is designed as a randomized, placebo-controlled, double-blinded study of 300 subjects randomized 1:1 to receive carboplatin and paclitaxel plus fosbretabulin versus carboplatin and paclitaxel plus placebo. The primary endpoint of the study will be to compare the median overall survival between the two arms.

Commented Peter J. Langecker, M.D., Ph.D., President and Chief Executive Officer: “We appreciate the FDA`s granting of the SPA for the pivotal FACT 2 trial of ZYBRESTAT in patients with anaplastic thyroid cancer. ATC is a tough disease — tough for patients who are faced with dire prospects, tough for doctors who have very little to offer in terms of therapy to their patients, tough for the company trying to develop a novel treatment and even tough for regulators who see the need but who also have to see certain criteria met to be able to approve a drug. We want to thank the agency for their very thoughtful and constructive process.

“ATC is the indication for which we have the most compelling data, suggesting an overall survival benefit for patients who receive ZYBRESTAT along with carboplatin and paclitaxel chemotherapy and that is the reason for our continued pursuit of this indication. ATC is a very rare tumor from which most patients die within few months of initial diagnosis, and thus represents a significant unmet medical need. We are hopeful that the receipt of the SPA will strengthen our ability to obtain funding to conduct the FACT 2 study, either through financing or partnering. We believe that vascular disrupting agents can make a valuable contribution to anticancer therapeutic regimens, and we look forward to advancing our VDA programs not only in ATC, but also in ovarian cancer, carcinoid syndrome, myeloid leukemia and other potential indications.” ABOUT ZYBRESTAT (FOSBRETABULIN TROMETHAMINE) ZYBRESTAT has been evaluated in a Phase 2/3 study of patients with anaplastic thyroid cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs).

Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against ATC, ovarian cancer and various other solid tumors.

BIOSANTE PHARMACEUTICALS INCORPORATED (NASDAQ: BPAX) “Up 8.02% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N46&L3&F=T BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante`s lead products include LibiGel (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S. Also in development are Bio-T-Gel, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook). Additional information is available online at www.biosantepharma.com.

BPAX News:

September 14 – Top Biotechnology Stock Picks from Oppenheimer & Company Research Analyst The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers.

Topics covered: Biotechnology and Pharmaceutical Valuations – Oncology Drug Development – Orphan Drugs – FDA Approval Process – Reimbursement Trends Companies include: Amgen Inc. (AMGN), Celgene Corporation (CELG), Celldex Therapeutics, Inc. (CLDX), Immunogen Inc. (IMGN), Curis Inc. (CRIS), Pluristem Therapeutics, Inc. (PSTI) and many others.

In the following excerpt from the Biotechnology and Pharmaceuticals Report, an expert analyst discusses the outlook for the sector:

TWST: What are some of the most exciting or promising new drugs, treatments or technologies coming out of your companies right now that investors should be aware of Mr. Peaker: The oncology space is actually very rapidly evolving, so let`s start with oncology first – I think that will be interesting. So oncology, and sometimes I guess in the same field people include immunology, is certainly a rapidly evolving space, where new data is presented quite frequently, and studies often don`t take a very long period of time compared to some other indications, like figuring cholesterol and things like that.

So in the oncology space, some of the interesting new developments are Celldex (CLDX) as a new drug in breast cancer, which is targeting a completely novel target, which is certainly exciting with some of the early stages of development, but the initial data is very encouraging. Speaking of breast cancer, ImmunoGen (IMGN) with their partner Roche (ROG.VX) – I don`t cover Roche, I cover ImmunoGen, but I follow certainly this space.

Also, it`s a very interesting breast cancer drug that shows very, very promising data. Furthermore, in cancer, Curis (CRIS) with its partner Genentech, recently launched a basal cell carcinoma drug, which is very exciting, and while it still needs a little time to figure out how to best use it, the efficacy is very, very encouraging.

On the cell therapy space, which is another area that I cover, there is a company, Pluristem (PSTI), a small company out there. It`s an Israeli-based company that has shown very interesting, certainly initial data, cell therapy treatments that may have broad applications. Let`s say Coronado Biosciences (CNDO) is another one that`s developing potentially breakthrough treatments, which is more in the immunology space, but it`s in Crohn`s, which is a broad indication where there are a lot of drugs that are being tested and are certainly approved. But their approach is very novel, and potentially could change the paradigm of treatment if successful. I don`t know if you want me to bring up more examples, but this is kind of a good start.

Prolor Biotech (PBTH) is another one that I might want to include there. It is a company that I initiated on just today, so I can speak about it already as developing. This is, as I mentioned, I have oncology and some orphan diseases, but a few companies out there that are, don`t fit into any particular category, and so what they`re developing, Prolor is developing a delayed-release growth hormone. So as you may know, growth hormone is used in a wide range of indications, some labeled and some are not labeled. And typically, every growth hormone that`s available out there requires daily injection. Prolor`s technology shows that their version of growth hormone is effective and may be given once a week, maybe every two weeks, but for now at least once a week. And we think it could be a game changer for the growth hormone market, which is well established at this point.

DARA BIOSCIENCES INCORPORATED (NASDAQ: DARA) “Up 22.22% on Tuesday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N46&L9&F=T DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA increased its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox, a novel oral liquid formulation of tamoxifen citrate which is widely used in the treatment and prevention of breast cancer. Soltamox is the only FDA approved oral liquid version of tamoxifen citrate and fulfills a vital clinical need for patients who cannot tolerate existing solid tablet formulations of this drug. DARA plans to begin marketing Soltamox in the U.S. later this year. Additionally, in June 2012 DARA launched its first product, Bionect, a topical treatment for skin irritation and burns associated with radiation therapy.

DARA News:

September 13 – Helsinn Grants to DARA Exclusive U.S. Commercial Rights to Gelclair, an FDA-Cleared Oral Gel for the Treatment of Oral Mucositis Gelclair Strengthens DARAs Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products The Helsinn Group of Switzerland announced today that it has entered into an exclusive agreement with DARA BioSciences, Inc. (Nasdaq: DARA) for U.S.

commercial rights to Gelclair. Gelclair is an FDA-cleared product indicated for the treatment of oral mucositis. DARA plans to launch Gelclair in the first quarter of 2013.

Oral mucositis is a painful inflammation and ulceration of the surface of the mouth and throat, which can result from a variety of cancer treatments.

Gelclair is a topical gel used to coat and protect the oral cavity to reduce pain.

David J. Drutz, MD, DARA`s chief executive officer, stated, “The exclusive agreement with Helsinn for rights to commercialize Gelclair is a significant milestone that provides us with an important commercial product in an area of significant medical need. Hundreds of thousands of cancer patients suffer from oral mucositis each year. Dr. Drutz continued, Helsinn offers DARA a respected partner with extensive experience in the oncology supportive care market. Our joint undertaking also provides the potential opportunity for a meaningful and long-term commercial and developmental relationship between our two companies.

Helsinn CEO, Riccardo Braglia, said We are excited to have a partner, in DARA, who has the same commitment to the oncology supportive care market as we do. We believe DARA will support Gelclair with the programs necessary to ensure health care providers and patients have this valuable product available as part of their treatment regimen. The shared vision of both Helsinn and DARA provides a sound foundation for a successful, long-term collaboration.

ABOUT ORAL MUCOSITIS The American Cancer Society estimates that approximately 400,000 patients annually will experience oral mucositis as a result of cancer treatment.

The National Cancer Institute estimates that almost 100 percent of patients receiving radiation therapy for head and neck cancers experience oral mucositis, as do 80 percent of patients undergoing hematopoietic stem cell transplantation and 40 percent of patients receiving standard-dose chemotherapy.

The consequences of mucositis are far-reaching and include pain, difficulty swallowing, interruption of chemotherapy or radiation treatment, administration of narcotics, hospitalization and, in the most severe cases, reliance on parenteral nutrition.

Gelclair provides a synergistic fit within DARAs oncology supportive care portfolio. DARAs three FDA-approved/cleared products (Bionect, Soltamox and Gelclair), and a fourth, gemcitabine, due for ANDA submission by end of 2012, are focused on the needs of oncology patients.

DARA licensed all four agents this year as part of its strategy to build a portfolio of niche opportunity products for the oncology and oncology supportive care markets.

DARA increased its focus in oncology treatment and supportive care products through its January 2012 acquisition of Oncogenerix, Inc. In June 2012, DARA launched its first product, Bionect, a topical treatment for skin irritation and burns associated with radiation therapy. It is preparing for the launch of Soltamox, the first and only FDA-approved oral liquid formulation of tamoxifen citrate, a widely used therapy for the prevention and treatment of breast cancer. Its product portfolio also includes KRN5500, a novel therapy under development for the treatment of neuropathic pain in patients with cancer, a condition with no current adequate therapy.

ABOUT HELSINN GROUP Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinns business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide.

Helsinns products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinns GMP facilities in Switzerland and Ireland and supplied worldwide to its customers.

OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it.

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N46&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N46&L=8&F=T.

Disclosure: OTCPicks.com is not currently being compensated by any of the companies covered in this release.

Related posts:

1. OTCPicks.com Daily Market Movers Digest Midday Report for Tuesday, September 18th
2. OTCPicks.com Stocks to Watch for Tuesday, September 18th
3. OTCPicks.com Daily Market Movers Digest Midday Report for Friday, September 14th
4. OTCPicks.com Stocks to Watch for Monday, September 17th
5. OTCPicks.com Stocks to Watch for Monday, September 17th